EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 207 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Tarlatamab Shows Promise in Patients with Previously Treated Small-Cell Lung Cancer October 31, 2023 FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer October 15, 2021 A Novel Model Helps Better Predict Risk of Cancer Development in... April 15, 2024 Classmates Surprise Badly Bullied Teen After Weeks Of Planning: ‘You Deserve... March 29, 2019 Load more HOT NEWS We have a Deal: What does the new UK-EU relationship mean... Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve... BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate...
